Full-Time

Scientist I

Upstream Development for Protein Development and Manufacturing

Posted on 10/7/2024

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$125k - $133kAnnually

Entry, Junior

San Carlos, CA, USA

Position requires onsite presence in San Carlos, CA.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in Chemical Engineering or a related discipline with minimum 2 years of relevant experience and may include postdoc. MS in Chemical Engineering with minimum 5 years of relevant experience. BS with minimum 8 years of relevant experience.
  • Strong background in cell free protein synthesis and characterization techniques.
  • Familiarity with DoE (Design of Experiments) principles and software.
  • Familiarity with regulatory requirements of biotherapeutics. Late-stage process characterization experience is a plus.
  • Experience with Ambr250 bioreactor system a plus.
Responsibilities
  • Design and execute small-scale CFPS process development and process characterization experiments in Ambr250.
  • Utilize advanced techniques and technologies to characterize and improve cell free synthesis processes.
  • Analyze experimental data and present results at project meetings.
  • Take an active role in technical documentation initiatives, including authorship of SOPs, technical reports, and ELN and database management.
  • Mentor junior team members.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop and commercialize broad-spectrum vaccines to improve global health outcomes, particularly for vulnerable populations.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

24%

1 year growth

63%

2 year growth

131%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Breakthrough Therapy designation for VAX-24 may accelerate its market entry.
  • Global pneumococcal vaccines market is projected to grow at a CAGR of 5.6% until 2030.
  • Recent $1.5 billion public offering strengthens Vaxcyte's financial position for future developments.

What critics are saying

  • Competition from mRNA technology developers like Moderna and BioNTech is intense.
  • Potential regulatory delays could impact Vaxcyte's clinical trial timelines.
  • Intellectual property disputes may arise over cell-free protein synthesis technology.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae bacteria.
  • Vaxcyte focuses on broad-spectrum vaccines for bacterial infections, unlike traditional methods.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE